6 active not recruiting, 5 recruiting, 1 completed, 1 not yet recruiting. 9 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 4, Recruiting 3, Completed 1, Not yet recruiting 1 |
| Phase 1 | 7 | Recruiting 3, Active not recruiting 2, Completed 1, Terminated 1 |
Follow Acute Myeloid Leukemia Post Cytotoxic Therapy: new trials by email Literature Review of Acute Myeloid Leukemia Post Cytotoxic Therapy trials Research Report on Acute Myeloid Leukemia Post Cytotoxic Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-22 |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) STX-0712 - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Recruiting | Solu Therapeutics, Inc | 105 | 2025-03-13 | 2026-02-09 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-21 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-21 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2023-10-10 | 2026-06-02 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2022-08-24 | 2026-06-30 |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Biospecimen Collection - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | PedAL BCU, LLC | 960 | 2022-04-18 | 2026-08-25 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2021-02-17 | 2026-06-12 |
| BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia Azacitidine, Biopsy Procedure, Biospecimen Collection - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2021-02-16 | 2026-08-03 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Biospecimen Collection, Bone Marrow Aspiration, Olaparib - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2020-08-04 | 2026-09-10 |
| Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine Phosphate - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Childhood Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 38 | 2016-05-02 | 2023-09-08 |
| Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Adavosertib, Belinostat, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Terminated | National Cancer Institute (NCI) | 20 | 2015-08-18 | 2026-01-30 |
| Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia Bortezomib, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 15 | 2013-07-03 | 2026-09-11 |
Leukemia, Myeloid, Acute (13) · Myelodysplastic Syndromes (6) · Myeloproliferative Disorders (3) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Blast Crisis (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Juvenile (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (13) · Hemic and Lymphatic Diseases (13) · Leukemia (13) · Leukemia, Myeloid (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Bone Marrow Diseases (8) · Chronic Disease (3) · Disease Attributes (3) · Myelodysplastic-Myeloproliferative Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2)
Specimen Handling (8) · Cytarabine (7) · Injections (7) · Biopsy (6) · Daunorubicin (6) · CPX-351 (5) · Liposomes (5) · Azacitidine (4) · venetoclax (4) · Decitabine (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Stem Cell Transplantation (2) · X-Rays (2) · decitabine and cedazuridine drug combination (2)
National Cancer Institute (NCI) (11) · Children's Oncology Group (1) · PedAL BCU, LLC (1) · Solu Therapeutics, Inc (1)
United States (13) · Canada (4) · Puerto Rico (3) · Australia (1) · New Zealand (1)
Amer M Zeidan (2) · Maria Luisa Sulis (2) · Alison R Walker (1) · Danielle A Shafer (1) · Ehab L Atallah (1) · Jerald P Radich (1) · Joshua F Zeidner (1) · Michele S Redell (1) · Paul J Shami (1) · Rory M Shallis (1) · Todd M Cooper (1)
UM1CA186689 (3), U10CA180886 (2), U10CA180888 (2), UM1CA186712 (2), UM1CA228823 (2), N01CM00100 (1), P30CA016058 (1), R01CA158350 (1), U01CA076576 (1), U10CA180820 (1), UM1CA186644 (1), UM1CA186716 (1)